Vivoryon Therapeutics N.V. to Report Q3 2024 Financial Results and Operational Progress on December 10, 2024
Vivoryon Therapeutics, a clinical stage company focused on developing small molecule medicines for modulating pathologically altered proteins, has announced it will release its Q3 2024 financial results and provide a corporate update on December 10, 2024.
The company will host a conference call and webcast at 3:00 pm CET / 9:00 am ET. The event will be accessible via phone through pre-registration and through a live audio webcast on Vivoryon's website. Participants are advised to join 15 minutes before the scheduled start time.
Vivoryon Therapeutics, un'azienda in fase clinica focalizzata sullo sviluppo di medicinali a piccole molecole per modulare le proteine alterate patologicamente, ha annunciato che rilascerà i suoi risultati finanziari per il terzo trimestre del 2024 e fornirà un aggiornamento aziendale il 10 dicembre 2024.
L'azienda ospiterà una conferenza telefonica e una webcast alle 15:00 CET / 9:00 ET. L'evento sarà accessibile tramite telefono previo registrazione e tramite una diretta audio sul sito web di Vivoryon. Si consiglia ai partecipanti di unirsi 15 minuti prima dell'orario di inizio programmato.
Vivoryon Therapeutics, una empresa en etapa clínica enfocada en desarrollar medicamentos de pequeñas moléculas para modular proteínas alteradas patológicamente, ha anunciado que publicará sus resultados financieros del tercer trimestre de 2024 y proporcionará una actualización corporativa el 10 de diciembre de 2024.
La empresa llevará a cabo una conferencia telefónica y una webcast a las 3:00 pm CET / 9:00 am ET. El evento será accesible por teléfono mediante preinscripción y a través de una transmisión de audio en vivo en el sitio web de Vivoryon. Se aconseja a los participantes unirse 15 minutos antes de la hora programada de inicio.
비보리온 테라퓨틱스는 병리적으로 변형된 단백질을 조절하기 위한 소분자 의약품 개발에 중점을 둔 임상 단계의 회사로, 2024년 3분기 재무 결과를 발표하고 2024년 12월 10일에 기업 업데이트를 제공할 것이라고 발표했습니다.
회사는 CET 오후 3시 / ET 오전 9시에 전화 회의 및 웹캐스트를 개최할 예정입니다. 이 이벤트는 사전 등록을 통해 전화로 접속 가능하며, 비보리온 웹사이트에서 실시간 오디오 웹캐스트로 진행됩니다. 참가자는 예정된 시작 시간 15분 전에 입장할 것을 권장합니다.
Vivoryon Therapeutics, une entreprise en phase clinique spécialisée dans le développement de médicaments à petites molécules pour la modulation des protéines pathologiquement altérées, a annoncé qu'elle publiera ses résultats financiers du troisième trimestre 2024 et fournira une mise à jour de l’entreprise le 10 décembre 2024.
L'entreprise tiendra une conférence téléphonique et une webdiffusion à 15h00 CET / 9h00 ET. L'événement sera accessible par téléphone via une préinscription et par un webinaire audio en direct sur le site Web de Vivoryon. Les participants sont invités à se joindre 15 minutes avant l'heure de début prévue.
Vivoryon Therapeutics, ein klinisch tätiges Unternehmen, das sich auf die Entwicklung von kleinen Molekülmedikamenten zur Modulation pathologisch veränderter Proteine konzentriert, hat angekündigt, dass es seine Finanzergebnisse für das 3. Quartal 2024 veröffentlichen und am 10. Dezember 2024 ein Unternehmensupdate geben wird.
Das Unternehmen wird eine Telefonkonferenz und einen Webcast um 15:00 Uhr CET / 9:00 Uhr ET veranstalten. Die Veranstaltung ist telefonisch nach vorheriger Registrierung sowie über einen Live-Audio-Webcast auf der Website von Vivoryon zugänglich. Den Teilnehmern wird geraten, 15 Minuten vor dem geplanten Beginn einzutreffen.
- None.
- None.
Vivoryon Therapeutics N.V. to Report Q3 2024 Financial Results and Operational Progress on December 10, 2024
Halle (Saale) / Munich, Germany, December 04, 2024 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that it will publish its third quarter financial results for the period ended September 30, 2024 and provide a corporate update on Tuesday, December 10, 2024. The Company will host a conference call and webcast open to the public.
Conference call details
Date: December 10, 2024
Time: 3:00 pm CET / 9:00 am ET
The conference call will be available via phone and webcast.
The live audio webcast of the call will be available on Vivoryon´s website at:
https://www.vivoryon.com/news-and-events/presentations-webcasts/
To join the conference call via phone, participants may pre-register and will receive dedicated dial-in details to easily and quickly access the call via the following website:
https://register.vevent.com/register/BIf0be17873ad0409b83edd4eedbe3b7ac
It is suggested participants dial into the conference call 15 minutes prior to the scheduled start time to avoid any delays in attendance.
###
About Vivoryon Therapeutics N.V.
Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines. Driven by its passion for ground-breaking science and innovation, the Company strives to change the lives of patients in need suffering from severe diseases. The Company leverages its in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings. The Company has established a pipeline of orally available small molecule inhibitors for various indications including Alzheimer’s disease, inflammatory and fibrotic disorders, including of the kidney, and cancer. www.vivoryon.com
Vivoryon Forward Looking Statements
This press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of Vivoryon Therapeutics N.V. (the “Company”), estimates and projections with respect to the market for the Company’s products and forecasts and statements as to when the Company’s products may be available. Words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should” and “will” and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management’s current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. The Company’s results of operations, cash needs, financial condition, liquidity, prospects, future transactions, strategies or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company’s future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law.
For more information, please contact:
Investor Contact
Vivoryon Therapeutics N.V.
Dr. Manuela Bader, Director IR & Communication
Email: IR@vivoryon.com
Media Contact
Trophic Communications
Valeria Fisher
Tel: +49 175 8041816
Email: vivoryon@trophic.eu
Attachment
FAQ
When will Vivoryon Therapeutics (VVY) release its Q3 2024 financial results?
What time is Vivoryon Therapeutics (VVY) Q3 2024 earnings call?
How can I access Vivoryon Therapeutics (VVY) Q3 2024 earnings call?
